PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and ribavirin for 6 months, developed progressive malaise and anemia 6 months after the end of treatment.
anemia
ribavirin
anemia
pegylated interferon alpha-2a
progressive malaise
pegylated interferon alpha-2a
progressive malaise
ribavirin